Fig. 5. Inhibition of MPXV replication by trifluridine and Adefovir dipivoxil (ADP).

(A) HFFs were infected with MPXV-WA-2003-Fluc (luc+MPXV) under an early/late promoter (MOI=0.01) treated with indicated compounds at indicated concentration for 24 h. Firefly luciferase activities were measured. The inhibition by AraC were normalized to 100. (B) MPXV-MA001 2022 isolate was added to cells at an MOI of 2 for 1 h. Virus was removed, cells were washed with PBS and trifluridine or adefovir dipivoxil was added at 10 μM. Cells were harvested 24 h post infection. AraC treatment was used as the positive control. Viral yields were titrated using a plaque assay on E6 cells. Each treatment was tested in triplicate. *p ≤ 0.05, **0.001<p ≤ 0.01, ***0.0001<p ≤ 0.001, ****0.00001<p ≤ 0.0001, ns, not significant.